NAV

Levocarnitine propionate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Levocarnitine propionate is a medication indicated in the treatment of peripheral arterial disease and to increase exercise tolerance in congestive heart disease.

Generic Name
Levocarnitine propionate
DrugBank Accession Number
DB15980
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 217.265
Monoisotopic: 217.131408096
Chemical Formula
C10H19NO4
Synonyms
  • L-Carnitine propionate
  • Propionyl-L-carnitine
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofObliterating arteriopathy of the lower limbs•••••••••••••••••••••• ••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Levocarnitine propionate hydrochloride12FW2YBF04119793-66-7Not applicable

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
0HU2UI27HF
CAS number
20064-19-1
InChI Key
UFAHZIUFPNSHSL-MRVPVSSYSA-N
InChI
InChI=1S/C10H19NO4/c1-5-10(14)15-8(6-9(12)13)7-11(2,3)4/h8H,5-7H2,1-4H3/t8-/m1/s1
IUPAC Name
(3R)-3-(propanoyloxy)-4-(trimethylazaniumyl)butanoate
SMILES
CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C

References

General References
  1. AIFA: Dromos (Levocarnitine Propionate) Intravenous Injection [Link]
Human Metabolome Database
HMDB0062514
ChemSpider
164090
ChEBI
53210
ChEMBL
CHEMBL3392074

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentIntermittent Claudication / Peripheral Vascular Disease Patient1
3CompletedTreatmentPeripheral Arterial Disease (PAD)1
3TerminatedTreatmentUlcerative Colitis2
2CompletedTreatmentUlcerative Colitis1
2RecruitingTreatmentHeart Failure With Preserved Ejection Fraction (HFpEF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for solutionParenteral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.152 mg/mLALOGPS
logP-2.3ALOGPS
logP-3.7Chemaxon
logS-3.2ALOGPS
pKa (Strongest Acidic)4.19Chemaxon
pKa (Strongest Basic)-7.1Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area66.43 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity77.26 m3·mol-1Chemaxon
Polarizability22.63 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-156.8817096
predicted
DarkChem Lite v0.1.0
[M-H]-157.8009796
predicted
DarkChem Lite v0.1.0
[M-H]-156.8637096
predicted
DarkChem Lite v0.1.0
[M-H]-143.61147
predicted
DeepCCS 1.0 (2019)
[M+H]+157.9083096
predicted
DarkChem Lite v0.1.0
[M+H]+158.7137796
predicted
DarkChem Lite v0.1.0
[M+H]+159.0367096
predicted
DarkChem Lite v0.1.0
[M+H]+146.00758
predicted
DeepCCS 1.0 (2019)
[M+Na]+157.6276096
predicted
DarkChem Lite v0.1.0
[M+Na]+157.3685796
predicted
DarkChem Lite v0.1.0
[M+Na]+157.6229096
predicted
DarkChem Lite v0.1.0
[M+Na]+152.03477
predicted
DeepCCS 1.0 (2019)

Drug created at December 07, 2020 14:07 / Updated at May 07, 2021 21:09